ChemicalBook
Chinese Japanese Germany Korea

Cinacalcet hydrochloride

Cinacalcet hydrochloride
Cinacalcet hydrochloride structure
CAS No.
364782-34-3
Chemical Name:
Cinacalcet hydrochloride
Synonyms
AMG-073 HCl;Cinacalcet HCl;Cinacalcet HCl,AMG073;AMG 073 (Hydrochloride);Cinacalcet hydrochlodide;Cinacalcet (AMG-073) HCl;Cinacalcet Hydrochloride;(R)-Cinacalcet Hydrochloride;AMG-073 HCl (Cinacalcet HCl);N-[(1R)-1-naphthalen-1-yleth
CBNumber:
CB71176208
Molecular Formula:
C22H23ClF3N
Formula Weight:
393.88
MOL File:
364782-34-3.mol

Cinacalcet hydrochloride Properties

Melting point:
175-177°C
storage temp. 
-20°C Freezer
CAS DataBase Reference
364782-34-3(CAS DataBase Reference)
SAFETY
  • Risk and Safety Statements
Safety Statements  24/25
HS Code  29214990

Cinacalcet hydrochloride price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 16042 Cinacalcet (hydrochloride) ≥95% 364782-34-3 10mg $65 2018-11-13 Buy
Cayman Chemical 16042 Cinacalcet (hydrochloride) ≥95% 364782-34-3 25mg $146 2018-11-13 Buy
Cayman Chemical 16042 Cinacalcet (hydrochloride) ≥95% 364782-34-3 50mg $244 2018-11-13 Buy
Cayman Chemical 16042 Cinacalcet (hydrochloride) ≥95% 364782-34-3 100mg $455 2019-12-02 Buy

Cinacalcet hydrochloride Chemical Properties,Uses,Production

Description

Cinacalcet is the first entry in a new class of therapeutic agents called the calcimimetics. It was launched as an oral treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in patients with parathyroid carcinoma. SHPT is associated with increased parathyroid hormone (PTH) secretion, which is triggered by low serum levels of calcium resulting from the failure of the kidney to clear phosphorous from the body and its inability to produce sufficient quantities of vitamin D. The consequences of increased PTH include stimulation of osteoclastic activity, cortical bone resorption and marrow fibrosis. PTH secretion is primarily regulated by the calcium-sensing receptor (CaR), which is located on the surface of the chief cell of the parathyroid gland. Calcimimetics bind to CaR and increase the sensitivity of CaR to extracellular calcium, thereby enabling its activation at subnormal levels of serum calcium. As a result, in the presence of these agents, the low levels of endogenous calcium in patients with renal failure are able to exert a suppressive effect on PTH secretion. Parathyroid carcinoma is also associated with elevated PTH levels, which are driven by autonomous parathyroid gland activity and subsequently lead to hypercalcemia. Although surgical resection is the primary therapy for treating hypercalcemia in parathyroid carcinoma patients, calcimimetics offer a nonsurgical alternative for patients with failed parathyroidectomy, metastatic parathyroid carcinoma, or high surgical risk. The recommended dosage of cinacalcet for the treatment of SHPT in chronic kidney disease is 30mg once daily at start and subsequent titration to 60, 90, 120 or 180 mg once daily. The dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma is 30 mg twice daily at start and subsequent titration to 60 or 90 mg twice daily, or 90mg three or four times daily as necessary to normalize serum calcium level. After oral administration of cinacalcet, maximum plasma concentration is achieved in approximately 2 to 6 hours. It has a terminal half-life of 30 to 40 hours and steady-state drug levels are reached within 7 days. Cinacalcet has a high volume of distribution (1000 L) and high protein binding (93%–97%). It is extensively metabolized in the liver, mainly by CYP3A4, CYP2D6 and CYP1A2. The primary routes of elimination are in the urine (80%) and in the feces (15%). In Phase III clinical trials involving 1136 patients with SHPT, administration of cinacalcet at 30–180 mg/day doses for 6 months produced 38–48% decrease in intact PTH. Overall, 64% of patients given cinacalcet achieved at least a 30% reduction in PTH, versus 11% of placebo patients. Calcium-phosphorous product was reduced 14% by the active treatment and did not change in the placebo group. In a much smaller clinical study involving 21 hypercalcemic patients with parathyroid carcinoma, administration of 60–360 mg/day doses of cinacalcet resulted in 71% of patients achieving a target reduction of ≥1 mg/dL in serum calcium. The most common adverse events in these trials were nausea and vomiting. In vitro, cinacalcet is a strong inhibitor of CYP2D6; therefore, dose adjustments may be required when coadministered with medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g. flecainide, vinblastine, thioridazine and most tricyclic antidepressants). Cinacalcet is prepared in a two-step synthesis starting from 3-[3-(trifluoromethyl)phenyl]propionaldehyde, by first condensing with (R)-(1-naphthyl)ethylamine to form the corresponding imine and subsequent reduction of the imine with sodium cyanoborohydride.

Chemical Properties

Off-White to Tan Solid

Originator

NPS pharmaceuticals (US)

Uses

Cinacalcet hydrochloride can be used in clinical trial in secondary hyperparathyroidism.

Definition

ChEBI: A hydrochloride derived from equimolar amounts of cinacalcet and hydrogen chloride.

brand name

Sensipar (Amgen).

Cinacalcet hydrochloride Preparation Products And Raw materials

Raw materials

Preparation Products


Cinacalcet hydrochloride Suppliers

Global( 227)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19918 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21686 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22633 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sale@mainchem.com CHINA 32447 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24191 60
Hebei Chisure Biotechnology Co., Ltd.
+8613292890173
0311 66567340 luna@speedgainpharma.com CHINA 1014 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 29996 58
Hebei Ruishun Trade Co.,LTD
17052563120
Mike@rsbiology.com CHINA 302 58
Hebei Huanhao Biotechnology Co., Ltd.
86-18034554576 whatsapp +8618034554576
86-0311-83975816 grace@hbhuanhao.com CHINA 721 58

View Lastest Price from Cinacalcet hydrochloride manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-07-03 Cinacalcet hydrochloride
364782-34-3
US $10.00 / KG 1KG 99% 10 mt Hebei Guanlang Biotechnology Co., Ltd.
2019-08-05 Cinacalcet hydrochloride
364782-34-3
US $1.00 / g 1g 99% 500kg Cangzhou Wanyou New Material Technology Co.,Ltd
2018-08-15 Cinacalcet hydrochloride
364782-34-3
US $1.00 / KG 1G 98% 100KG career henan chemical co

364782-34-3(Cinacalcet hydrochloride)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved